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Abstract CD40 is a member of the tumor necrosis factor 
receptor (TNF-R) family that regulates B-lymphocyte prolifera- 
tion, immunoglobulin class-switching, and apoptosis through 
poorly defined signal transduction mechanisms. Using a yeast 
two-hybrid method, cDNAs were obtained that encode a novel 
protein, CD40-associated protein-1 (CAP-I), which binds specif- 
ically to the cytosolic domain of CD40 but not TNF-R1, TNF-R2, 
or Fas. The CAP-1 protein contains a C-terminal domain that 
shares strong amino acid sequence homology with a unique do- 
main found recently in two putative signal transducing proteins 
that bind to the TNF-R2 cytosolic tail, TRAF1 and TRAF2. This 
C-terminal region of CAP-1 was sufficient to mediate binding to 
CD40 and homodimerization of CAP-1 proteins. The N-terminal 
portion of CAP-1 contains a RING finger motif and three zinc 
finger-like domains similar to those found in several regulatory 
proteins that interact with DNA or RNA. CAP-1 thus represents 
a new member of a family of potential signal transducing proteins 
that contain a conserved omain (the TRAF domain), bind to the 
cytosolic regions of particular members of TNF-R family pro- 
teins, and that can form homo- and heterotypic dimers. 
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1. Introduction 
CD40 is a -50-kDa glycoprotein receptor that is expressed on 
the surface of B-lymphocytes, ome activated T-cells, mon- 
ocytes, follicular dendritic ells, basal epithelial cells as well as 
some epithelial and non-epithelial carcinomas. The functions 
of this receptor have been most extensively studied in B-cells, 
where it is believed to play an important role in regulation of 
proliferation and apoptosis, immunoglobulin class-switching, 
generation of memory B-cells, modulation of cytokine gene 
expression, and cell adhesion (reviewed in [1-3]). The ligand for 
CD40 is expressed on the surface of activated helper T-cells, as 
well as mast cells and basophils, as a type-II transmembrane 
glycoprotein [4-6]. CD40-L thus triggers CD40 through a 
mechanism involving cell-cell contact. The importance of the 
CD40/CD40-L interaction for the regulation of T-cell-depend- 
ent humoral immune responses has been demonstrated by ex- 
periments where antibodies to CD40-L were shown to inhibit 
the generation of primary and secondary humoral immune 
responses [7]. Moreover, mutations in the CD40-L in humans 
cause an X-linked immunodeficiency s ndrome characterized 
by excess production of IgM and absence of production of IgG, 
IgA, and IgE caused by a failure of B-cells to undergo Ig 
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class-switching [8-10]. Thus, CD40-L/CD40 interactions ap- 
pear to be essential for Ig class switching in vivo. Likewise, 
transgenic mice with homozygous disruptions of their CD40 
genes fail to form germinal centers and do not produce IgG, 
IgA, and IgE response to thymus-dependent a igens but can 
mount normal IgM and IgG responses to T-independent anti- 
gens [11]. Antibodies to CD40-L prevent collagen-induce ar- 
thritis in animal model [12], suggesting that inhibition of CD40- 
triggering could provide a means of therapeutically intervening 
in some types of autoimmune dieases. The expression of CD40- 
L on mast cells and basophils has also been reported to mediate 
induction of IgE synthesis by B-cells when co-stimulated with 
IL-4 [6], implying an important role for CD40-L/CD40 interac- 
tions in atopic diseases. 
CD40 and its ligand are members of the Tumor Necrosis 
Factor Receptor (TNF-R) family and TNF-family, respec- 
tively. The TNF-R family includes the p50/55-TNF-R 1, p75/80- 
TNF-R2, p75-Nerve Growth Factor (NGF) Receptor, CD27, 
CD30, Fas, among others [13]. The predicted cytoplasmic do- 
main of CD40 contains just 62 amino-acids and bears no resem- 
blance to kinases or other enzymes that might suggest a mech- 
anism by which this protein transduces signals into cells [14]. 
A region within the cytoplasmic domain of CD40 however has 
limited homology to a conserved omain found in the cytosolic 
tails of p75-NGF-R (22%), TNF-RI(31%), and Fas (41%). In 
TNF-R1 and Fas, this conserved omain is required for induc- 
tion of signals resulting in cell death [15,16]. Interestingly, 
though best known for their roles in generating signals that 
suppress apoptosis, both CD40 and p75-NGF-R have been 
shown to paradoxically accelerate apoptosis when ectopically 
expressed in certain neural cell lines in the absence of ligands 
[17,18]. In these same cells, CD40 and p75-NGF-R can also 
delay cell death relative to untransfected cells when triggered 
with appropriate ligands. Thus, it is possible that CD40 and 
NGF-R (like TNF-R and Fas) can regulate signal transduction 
pathways leading to cell death under some circumstances. To 
gain further insights into the mechanisms by which CD40 
transduces signals into cells, we used a yeast two-hybrid ap- 
proach to clone cDNAs that encode proteins capable of specif- 
ically binding to the cytosolic domain of this receptor. A novel 
protein was thus discovered which we have termed CAP-1 for 
CD40-associated protein- 1. 
2. Materials and methods 
2.1. Plasmid constructions 
The cDNA encoding various fragments of CD40 were generated by 
PCR from the plasmid pCDM8-CD40 (gift of B. Seed) [14] using the 
following forward (F) and reverse (R) primers containing EcoRI (un- 
derlined) and Bcll (italic) sites (bold indicates top codon): CD40 (216 
277), 5'-GGAATTCAAAAAGGTGGCCAAG-3' (F1) and 5'-TGA- 
TCATCACTGTCTCTCCTGCAC-3"(RI); and CD40 (225 269), 
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5'-GGAATTCAAGGCCCCCCACCCCAAG-3' (F2) and 5"-TG- 
ATCAACTCTCTTTGCCATCCTC-3" (R2). The PCR products 
were digested with EcoRI and Bcil, then directly cloned into the EcoRI 
and BarnHI sites of the yeast wo hybrid plasmid pBTM 116 (gift of 
S. Hollenberg, U. Washington; Seattle) in frame with the upstream 
LexA DNA-binding domain sequences [19]. For expression of LexA- 
Fas and LexA-TNF-R2 fusion proteins in yeast, the cytosolic domains 
of Fas and TNF-R2 were amplified by PCR from the plasmids pBS- 
APO 14.1 (gift of P. Krammer) and pBluescript-p80-TNF-R2 (gift of C. 
Smith, Immunex, Inc., Seattle, WA), respectively, using the primers 
5'-GGAATTCAAGAGAAAGGAAGTACA- 3'(forward/Fas) and 
5"-GTGATCACTAGACCAAGCTTTGGAT-3" (reverse/Fas) and 
5'-GGAATTCAAAAAGAAGCCCTTGTGCCT- 3' (forward/TNF- 
R2) and 5"-GGTCGA CITAACTGGGCTTCATCCCA-3'(reverse/ 
TNF-R2). The Fas PCR product was digested with EcoRI and Bcil and 
cloned into EcoRI/BamHI-digested pBTM-116, whereas the TNF-R2 
PCR product was digested with EcoRI and Sail and cloned into EcoRI/ 
XhoI-digested pBTM 116. Additional pBTM 116 plasmids encoding 
portions of the Bcl-2, Ha-Ras (VI 2), and Lamin-C proteins have been 
described [19,20]. 
For expression as GST-fusion proteins in E. coli, the pBTM 116- 
CD40 (225-269), Fas, and TNF-R2 plasmids were digested with EcoRI 
and either XhoI or Sail and the inserts subcloned in-frame with the 
upstream GST sequences in pGEX-4T-1. For GST-CD40(220-277), a 
Ball fragment encoding amino-acids 220 277 was excised from 
pCDMS-CD40 and subcloned initially into the HinclI site of Bluescript 
pSKII (Stratagene, Inc., La Jolla, CA). The pSKII-CD4OIBaii plasmid 
was then cut with XhoI and EcoRI and the CD40 sequences subcloned 
into a modified verion of pGEX-2T-1 in frame with the GST sequences. 
For GST-TNF-R 1, the cytoplasmic domain of TNF-R 1 was PCR am- 
plified from the plasmid pUC19-p55-TNF-R1 (gift of W. Lesslauer; 
Hoffmann La-Roche Inc., Basal, Switzerland) using the primers 
5"-GGGATCCGCTACCAACGGTGGAAG-3' (forward/TNF-R 1) 
and 5'-GGTCGACTCATCTGAGAAGACTGGG-3" (reverse/TNF- 
R1), digested with BamHI and Sail and subcloned into pGEX-5X-1. 
For GST-CAP-1, the pACT-2229 cDNA was digested with BgllI, and 
the CAP-1 cDNA (363-543) was subcloned into pGEX-3X. 
2.2. Two-hybrid assays 
Library screening by the yeast wo-hybrid methods was performed 
as described [19,21] using a human B-cell library in lambda-ACT (gift 
of S. Elledge, Baylor; Houston, TX) and L40 strain S. cerevisiae 
[MATa, trpl, leu2, his3, ade2, LYS2:(lexAop)4-HIS3, URA3.: 
(lexAop)S-lacZ]. Cells were grown in either YPD medium with 1% 
yeast extract, 2% polypeptone, and 2% glucose, or in Burkholder's 
minimal medium fortified with appropriate amino-acids as described 
previously [20]. Transformations were performed by a LiC1 method 
using 0.5 mg of pACT-cDNA library DNA, 1 mg of denatured salmon 
sperm carrier DNA, and ~ 5 × 109 L40-strain cells. The mating strain was 
NA87-11A (MATer, leu2, his3, trpl, pho3, pho5) which had been trans- 
formed with pBTM 116 plasmids producing CD40 cytoplasmic domain 
or various control proteins and selected on tryptophan-minus media. 
To confirm the specificity of interactions, 5/~g of various pBTMll6 
plasmids and 5/lg of either pACT-121 or pACT-2229 were transformed 
into L40 cells and plated on semi-solid media lacking tryptophan and 
leucine. Colonies were then transfered to histidine-deficient plates or 
histidine-containing media with X-gal. fl-Galactosidase plate assays 
were performed ~12 h later and filter assays hrs later as described 
previously [20]. 
2.3. In vitro protein-binding assays 
The CAP-1 cDNA was PCR amplified using a forward primer con- 
taining a T7 promoter (5'-TAATACGACTCACTATAGGGAGAC- 
CACATGGATGATGTATATAACTATCATTTC-3') and a reverse 
primer (5'-CTACCAGAATTCGGCATGCCGGTAGAGGTGTGG- 
TCA-3') from 1 /lg of pACT-2229 plasmid DNA. One-tenth of the 
resulting PCR product (-0.1/.tg) was then directly transcribed and trans- 
lated in vitro in the presence of [35S]methionine using 12.5/.tl of reticu- 
locyte lysate (TNT-Lysate; Promega, Inc.; Madison, WI). Glutathione- 
Sepharose bead containing 5/lg of GST fusion proteins were incubated 
with 10/11 of in vitro translated protein in 50 mM Tris (pH 8.0), 150 
mM NaC1, 5 mM DTT, 2 mM EDTA, 0.1% NP-40, 1 mM PMSF, and 
1/~g/ml leupeptin for 16 h at 4°C. The beads were washed vigorously 
5 × in the same solution, pelleted by centrifugation, and boiled in 
Laemmli sample buffer before analysis by SDS-PAGE and fluorogra- 
phy. 
For experiments with cell lysates, 2 x 10  7 RS11846 B-cell lymphoma 
cells were lysed in 0.25 ml of ice-cold 10 mM Tris (pH 7.4), 150 mM 
NaC1, 5 mM EDTA, 1% Triton X-100, with protease inhibitors (PMSF, 
aprotinin, leupeptin, benzamidine, and pepstatin) and nuclei and debris 
were removed by centrifugation as described. The resulting superna- 
rants were then incubated with 5/tg of affinity-purified GST-CAP-1 
(363-543) or GST-control protein immobilized on 50 ¢tl of glutathione- 
Sepharose beads for ~ 16 h at 4°C, then washed x 10 in 50 mM Tris (pH 
7.4), 150 mM NaC1, 5 mM EDTA, 0.1% NP-40, 1 mM PMSF, 1 ,ug/ml 
leupeptin. Proteins adsorbed to beads were then boiled in Laemmli 
sample buffer and analyzed by SDS-PAGE (12% gels) and transfered 
to nitrocellulose. The resulting blots were preblocked in Tris-buffered 
saline (pH 7.4) containing 5% non-fat milk and 3% bovine serum albu- 
min (BSA) and then incubated with 2 ¢tl/ml of anti-human CD40 mon- 
oclonal antibody B-B20 (Biosource, Inc.; Camarillo, CA) followed by 
horseradish peroxidase-conjugated goat anti-mouse IgG and detection 
using an ECL method (Amersham, Inc.). 
2.4. Screening of cDNA libraries and RT-PCR 
The insert from pACT-2229 was excised with XhoI, 32p-labeled by a 
random primer method, and used to screen a human fetal brain cDNA 
library (Clonetech, Inc.) in )t.-gtl 1. Two cDNA clones were obtained, 
PCR amplified using primers flanking the cloning site in 2-gtl 1, and 
the resulting PCR products were subcloned into a EcoRV-digested, 
T-tailed pSK-II plasmid and their DNA sequence determined by the 
dideoxynucleotide m thod. 
For 5'-RACE, 10/tg of total RNA from Raji B-cell lymphoma cells 
was reverse-transcribed using a specific primer 5'-GCGTTAACTGC- 
TCTGCACAA-Y and recombinant Moloney murine leukemia virus 
reverse transcriptase (Gibco/BRL, Inc.; Gaitherburg, MD). The result- 
ing cDNA was subjected to homopolymeric tailing using dCTP and 
terminal deoxynucleotidyl transferase using a kit from BRL/GIBCO, 
and then PCR amplified using a universal 5'-anchor primer provided 
by the manufacturer and a CAP-l-specific reverse primer 5'-GTACA- 
TTTTGGACTTGAAGA-3'. The final PCR product was subcloned 
into T- tailed pSK-II and sequenced. 
3. Results 
3. I. Cloning of cDNAs encoding a CD40-binding protein by 
yeast two-hybrid method 
A yeast two hybrid approach was employed to attempt o 
clone cDNAs encoding proteins capable of binding to the cyto- 
plasmic domain of CD40. For these experiments, the entire 
cytoplasmic tail of CD40 (amino-acids 216-277) was expressed 
in yeast as a fusion protein with an NH2-terminal LexA DNA 
binding domain. Yeast were then transformed with a human 
B-cell cDNA library in an plasmid that expresses random 
cDNAs as fusion proteins with a Gal4 trans-activation domain. 
Positive interactions between the LexA-CD40 bait protein and 
Gal-4-fusion proteins were detected using either a HIS3 gene 
or lacZ gene under the control of lexA operators. From an 
initial screen o f~3 × 107 transformants, 2 640 clones were iden- 
tified that trans-activated the HIS3 reporter gene based on 
ability to grow on histidine-deficient media. Of these, 166 were 
also produced fl-galactosidase. These 166 candidate transfor- 
mants were then cured of the LexA/CD40 bait plasmid by 
growth in media containing tryptophan and then mated with 
each of 4 different indicator strains of cells containing one of 
the following LexA bait proteins: cytosolic domain of CD40 
(amino-acids 216-277), cytoplasmic domain of Fas (191-335), 
Bcl-2 (83 218), or Lamin-C. This resulted in just two clones 
that grew on histidine-deficient media and produced fl-galacto- 
sidase when expressed in combination with the LexA-CD40 
bait protein but not the other 3 control LexA fusion proteins. 
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DNA sequencing demonstrated that these represented identical 
cDNAs, presumably arising during library amplification. An 
open reading frame of 543 bp (181 amino-acids) followed by 
a stop codon and a ~457 bp Y-untranslated region was identified 
fused with the upstream Gal4 trans-activation domain se- 
quences (hereafter termed CAP-l). 
3.2. CAP-1 interacts with a subregion of the CD40 cytoplasmic 
domain that is conserved in some other members of the TNF 
receptor family 
The GaI4/CAP-1 plasmids identified through the cDNA li- 
brary screening experiment described above were isolated and 
retransformed into yeast cells with various LexA fusion pro- 
teins to confirm their ability to bind to the cytoplasmic domain 
of CD40 in two-hybrid assays. As summarized in Table 1, the 
CAP-1 protein fragment interacted with LexA fusion proteins 
containing not only the complete cytosolic domain of CD40 
(amino-acids 21(~277), but also a smaller portion of this do- 
main (amino-acids 225-269) that has homology to a conserved 
domain found in the cytosolic domains of TNF-R1, Fas, and 
the p75 subunit of the NGF receptor [22]. CAP-l, however, 
failed to interact with the cytoplasmic domains of Fas and 
TNF-R2 in these two-hybrid experiments, aswell as a variety 
of other proteins, including Ha-Ras, Bcl-2, and Lamin-C. 
3.3. Interactions of CAP-1 with CD40 cytoplasmic domain 
demonstrated by in vitro binding assays 
To confirm the interaction of CAP-1 with the cytoplasmic 
domain of CD40, in vitro binding assays were performed using 
in vitro translated CAP-1 and affinity-purified GST-CD40 fu- 
sion proteins. For these experiments, the CAP-1 cDNAs iden- 
tified by library screening were transcribed and translated in 
vitro using rabbit reticulocyte lysates in the presence of [35S]L- 
methionine. The resulting 35S-labeled CAP-I protein was then 
incubated with various GST-fusion protein, as indicated in Fig. 
IA. Using this in vitro binding assay, CAP-1 was shown to 
interact specifically with GST-fusion proteins containing the 
nearly full-length CD40 cytoplasmic domain (220-277) as well 
as the conserved subregion of the CD40 cytosolic domain (225- 
269). No interactions were detected in vitro between 35S-labeled 
CAP-1 and GST-fusion protein containing the cytosolic do- 
mains of Fas, TNF-R1, or TNF-R2 (Fig. 1A). CAP-1 also did 
not interact with a GST non-fusion protein but did interestingly 
Table 1 
Specific interaction of CAP-1 with CD40 cytoplasmic domain 
pBMT116 (LexA) pACT (Gal4) His fl-Gal 
CD40 (216,277) 2229 + + 
CD40 (225 269) + + 
TNFR2 (288-461) 
Fas (191 335) 
Ras (V12) 
Bcl-2 (83-218) 
Lamin-C 
pBTM 116 plasmids producing LexA DNA-binding domain fusion pro- 
teins (listed at left) were co-transformed with pACT-CAP-1 (clone 
2229) which encodes the C-terminal 181 amino-acids ofCAP-1 fused 
to a Gal-4 trans-activation domain (5 #g each) into L40 stain yeast. 
Transformed cells were grown on semi-solid media lacking histidine or 
containing histidine as a control. Plasmid combinations that resulted 
on growth on histidine-deficient media were scored as positive (+). 
fl-galactosidase activity of each colony was tested by filter assay and 
scored as blue (+) versus white (-). 
A 
79 
50 
35 
28 
2O .91 
B 
'88= 
50-  
33-- 
i 
Fig. 1. In vitro binding of CAP-1 to CD40 cytoplasmic domain and 
CAP-1 C-terminal domain. In (A), various GST-fusion proteins as 
indicated were affinity-purified onglutathione-Sepharose. Beads con- 
taining ~5 #g of GST-proteins were incubated with 35S-c-methionine- 
labeled in vitro translated CAP-1 (C-terminal 181 amino-acids). After 
extensive washing, beads were boiled in Laemmli buffer and the eluted 
proteins were subjected to SDS-PAGE followed by fluorographic de- 
tection of 35S-CAP-1 protein (bold arrow) which migrated as a doublet 
here, presumably due to translation from both the first AUG of Gal-4 
in pACT-2229 as well as an internal start codon located either 4 or 15 
residues downstream (from multiple cloning site of pACT). In (B), 
GST-CAP-1 (C-terminal 181 amino-acids)and GST control proteins 
were immobilized on glutathione-Sepharose and incubated with deter- 
gent lysates prepared from RS 11846 B-cell ymphoma cells. Beads were 
washed extensively, and associated proteins were eluted by boiling in 
Laemmli buffer followed by SDS-PAGE and transfer to nitrocellulose 
filters. RS 11846 cell ysates were also run directly in the gel as a positive 
control (far right lane). The resulting blot was incubated with anti- 
CD40 monoclonal ntibody B-B20, which was detected subequently 
by an ECL method using 10 min exposed to X-ray film. The position 
of CD40 is indicated by the bold arrow. 
interact with GST-CAP-1, implying that CAP-1 can homod- 
imerize. The specificity of these results was further confirmed 
by experiments where a variety of other 35S-labeled in vitro 
translated proteins including Bcl-2, Bax, Lyn were tested and 
found not to bind to GST-CD40 fusion proteins under the same 
conditions used here of 3~S-CAP-I (not shown). 
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CAP-1 MESSKKMDSP GALQTNPPLK LHTDRSAGTP VFVPEQGGYK EKFVKTVEDK 50 
TRAF2 MAAA-SVTSP GSLELLQP-G FSKTLLGTRL EAKYLCSACK NILRRPFQAQ 48 
TRAFI MASS-S- -AP  DENE-FQF-G CPPAPCQDPS EPRVLC--CT ACLSENLRDD 43 
Consensus  MASS-S . .SP  G .LE . .QP-G . . . . . . . . . .  E . . . LC . ,CK  . . L  . . . . .  D.  50 
CAP-1 YKCEKCHLVL CSPKQTECGH RFCESCMAAL LSSSSPKCTA CQBSIVKDKV i00 
TRAF2 CGHRYCS--F  CLTSILSSGP QNCAACVYEG LYEEG--- IS ILESSS---A 90 
TRAFI -EDRICP--K CRADNLHPVS PGSP--LTQE KVHSD---VA EABIMC---P 82 
Consensus  . , ,R .C . - - .  C . . . .  L . .G .  . .C . .C  . . . .  L . .S . - - - .A  . .BS . . - - - .  i00 
CAP-1 FKDNCCKREI  LALQIYCRNE SRGCAEQLTL GHLLVHLKND CHFEELPCVR 150 
TRAF2 FPDNAARREV ESLPAVCPND --GCTWKGTL KEYESCHEGL CPF--LLTEC 136 
TRAFI FAG . . . . . . . . . . .  VGCSFK --GSP--QSM QEHEATSQSS HLY--LL---  112 
Consensus  F .DN. . .RE .  . . L . . .C .N .  - -GC . . . .  TL  .E .E  . . . . . .  C .F - -LL . . .  150 
CAP-1 PDCKEKVLRK DLRDHVEKAC KYREATCSHC KSQVPMIALQ KHEDTDCPCV 200 
TRAF2 PACKGLVRLS EKEHHTEQEC PKRSLSCQHC RAPCSHVDLE VHYEV-CPKF 185 
TRAFI . . . . .  LAVL- -KEW---KSS PGSNLG .... SAP---MALE RNL .... SEL 141 
Consensus  P .CK .  LV .L .  .KE .H .  EK .C  P .R .L .C .HC .AP  . . . .  ALE  .H . . . -CP . .  200 
CAP-1 VVSCPHKCSV QTLLRSBGTN QQIKAHEASS AVQHVNLLKE WSNSLEKKVS 250 
TRAF2 PLTC-DGCGK KKIPR-ETFQ DHVRACSKCR VLCRFHTVG- -CSEMVETEN 231 
TRAFI QL . . . . . . . . .  QAAV-EATG DLEVDC--YR APC . . . . . .  C .. . . . .  ES 165 
Consensus  .L .C - . .C  . . . . . .  R -B .T .  D . . .AC . . .R  A .C  . . . . . .  - -C  . . . . . .  ES  250 
CAP-1 LLQNESVEKN KSIQSLHNQI CSFEIEIERQ KEMLRNNESK ILHLQRVIDS 300 
TRAF2 -LQDHELQRL REHLAL--LL SSF-LEAQAS PGTLNQVGPE LLQRCQILE- 276 
TRAFI -QEELALQHL . . . . . . . . . . . . . . . . . . . . . . . . .  VKEK LLAQ---LE- 184 
Consensus  - LQ. . . LQ.L  . . . . .  L - - . .  .SF - .E  . . . . . . .  L , .V . .K  LL  . . . . .  LE -  300 
CAP-1 QAEKLKELDK EIRSFRQNWE RADSMKSSVE SLQNRVTELE $VDKSAGQVA 350 
TRAF2 - -QKIATFEN IVCVLNRE-V RRVAVTAEAC SRQHRL-DQD KIEA ...... 316 
TRAFI - -EKLRVFAN IVAVLNKE-V EASHLALAAS IHQSQL-DRE HLLS ...... 224 
Consensus  - -EKL . .F .N  IV .  VLN.E -V  BA . . . . . .  A .  S .Q .RL -D .E  . . . .  - . . . . .  350 
CAP-1 RNTGLLESQL SRHDQMLSVH DIRLADMDLR FQVLHTASYN GVLIWKIRDY 400 
TRAF2 ..... LSNKV QQLERSIGLK DLAMADLEQK VSELBVSTYD GVFIWKISDF 361 
TRAFI ..... LEQRV VELQQTLAQK DQVLGKLEHS LRLMBEASFD GTFLWKITNV 269 
Consensus  . . . .  LE . .V  . . L ,Q .L . .K  D . .LADLE . . . . .  LB .ASYD GVF IWKI .  D. 400 
CAP-1 KRRKQEAVMG KTLSLYSQPF YTGYFGYKMC ARVYLNGDGM GKGTHLSLFF 450 
TRAF2 TRKRQEAVAG RTPAIFSPAF YTSRYGYKMC LRV~DGT GRGTHLSLFF  411 
TRAFI TKRCHBSVCG R~VSLFSPAF YTAKYGYKLC LRLYLNGDGS GKKTHLSLFI  319 
Consensus  TRR.QBAV.  G RT .  SLFgPAF  I"1'.. YGYKMC LRV~LNGDG.  GKGTHDSLFF  450 
CAP-1 V IMRGEYDAL LPWPFKQKVT LMLMDQGSSR RHLGDAFKPD PNSSSFKKPT 500 
TRAF2 9"VMKGPNDAL LQWPFNQK%'T LMLLDH-NNR EHVIDAFRPD VTSSSFQRPV 460 
TRAFI V IMRGEYDAL LPWPFRNKVT FMLLDQ-NNR EHAIDAFRPD LSSASFQRPQ 368 
Consensus  VIMRGEYDALLPWPF.  QKVTLKLLDQ-NNR EH.  IDAFRPD . .gSSFQRP.  500 
CAP-1 GEMNIASGCP VFVAQTVLE-  -NGTYIKDDT IFIKVIVDTS DLPDP 543 
TRAF2 SDMNIASGCP LFCPVSKME- AKNSYVRDDA IFIKAIVD-- -LTGL 501 
TRAFI SETNVASGCP LFFPLSKLQS PKHAYVKDDT MFLKCIVD . . . .  TSA 409 
Consensus  S EMNIASGCP LF .  P. S KLE-  . K .  . YVKDDT IF IK .  IVD-  - - L T. . 545 
Fig. 2. Alignment of predicted amino-acids equences of CAP-I with TRAF1 and TRAF2. An alignment of the predicted amino-acids equences 
of the human CAP-l, TRAF2, and TRAF1 proteins is shown. Residues that are identical in all three proteins are shown in bold type. A concensus 
sequence is provided below in italics, with residues that are shared among two of the three proteins in plain type and residues that are identical in 
all three proteins in bold type. 
As another approach to examining the interaction of CAP-1 
with CD40, in vitro binding experiments were performed using 
cell lysates derived from an CD40-expressing human B-cell 
lymphoma cell line RSl1846. GST control protein or GST- 
CAP-1 fusion protein were immobilized on glutathione-Sepha- 
rose beads and mixed with detergent-lysates from RSl1846 
cells. After thorough washing, the beads were pelleted by cen- 
trifugation and associated proteins were subjected to SDS- 
PAGE/immunoblot assays with anti-CD40 antibody, de- 
monstrating the presence of CD40 in samples containing the 
GST-CAP-1 protein but not the GST control protein (Fig. 1B). 
3.4. Determination of the complete open reading frame of the 
CAP-1 protein reveals a new member of the TRAF family 
of putative signal transducing proteins 
A human fetal brain cDNA library was screened and two 
additional overlapping clones having insert sizes of -2.0 kbp 
and 0.1 kbp were obtained. The DNA sequence of the longer 
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of these extended the coding region in the 5'-direction by an- 
other 282 amino-acids but suggested that the complete ORF 
had still not been obtained. A 5'-RACE (rapid amplification of 
cDNA ends) procedure was then used to obtain an additional 
378 bp of DNA sequence. Taken together these cDNA cloning 
results demonstrated the presence of a continuous ORF pre- 
dicted to encode a 543 amino-acid protein, having an estimated 
molecular mass of ~62 kDa (Fig. 2). The predicted translation 
initiation site conforms well to the Kozak consensus sequence, 
with 6 of 7 matches. Stop codons were found in all three read- 
ing-frames upstream of the longest ORF (nucleotide sequence 
submitted to Genbank). 
A search of the CAP- 1 nucleotide sequence against he avail- 
able databases using the BLAST program revealed 26% and 
30% overall amino-acid sequence homology with TRAF1 and 
TRAF2, two putative signal transducing proteins that have 
recently been shown to bind to the cytosolic domain of TNF- 
R2 [23]. The strongest homology was located in the C-terminal 
regions of these proteins, corresponding to the 'TRAF' do- 
mains of TRAF1 and TRAF2 (Fig. 2). The TRAF domain of 
CAP-1 is located between residues 384 to 540, and has 57% and 
59% amino-acid identity to the analogous domains in TRAF1 
and TRAF2, respectively. 
Like TRAF2, the CAP-1 protein contains a RING finger 
domain near its NH2-terminus (residues 53-91) having the con- 
sensus motif C-X2-C-X l l _ I2 -C -X1_3-H-X2-C-X2-C-X I~ I3 -C-X  2 - 
C. This sequence is believed to form a structure that binds two 
zinc atoms and is found in several regulatory proteins that can 
bind to either DNA or RNA, including the DNA repair genes 
RAD18 of S. cerevisiae and UVS-2 of Neurospora crassa, the 
human SS-A/Ro ribonucleoprotein, the Bmi-1, C-dbl, Pml, and 
RET proto-oncogenes, the recombinase RAG-l, and the 
human RING-1 protein (reviewed in [24]). The RING finger 
domains of CAP-I and TRAF2 are 42% identical. 
Following the RING finger motif are two zinc finger do- 
mains in CAP-1 that contain the consensus sequence C/H-X2~ 
-C/H-X2_~5-C/H-X2 -C/H which is found in several DNA-bind- 
ing proteins including the Xenopus transcription factor TFII IA 
[25] as well as some RING-finger proteins uch as RAD18, and 
UVS-2 (reviewed in [24]). A third zinc-finger-like domain is 
found in CAP-1 (between residues 117-141), but the spacing 
between the first two cysteines i longer than usual in this case 
(6 instead of usual 2 to 4). The TRAF2 protein also contains 
four zinc finger motifs downstream of its RING finger domain 
[23]. Taken together, these data indicate that CAP-1 is a novel 
homolog of TRAF2 and a new member of the family of puta- 
tive signal transducing proteins that contain TRAF-domains. 
4. Discussion 
Using a yeast two-hybrid approach, cDNAs encoding a 
novel protein CAP-1 that binds specifically to the cytosolic 
domain of CD40 were obtained. The region in the cytosolic 
domain of CD40 that is sufficient for CAP-1 binding consti- 
tutes a 45 amino-acid omain (residues 225-269) that is weakly 
homologous (2241%) to domains found in the cytosolic por- 
tions of TNF-R1, Fas, and p75-NGF-R. This domain has been 
shown to be required for TNF-R 1- and Fas-based cytotoxicity 
[ 15,16], suggesting that it plays an important role in some aspect 
of signal transduction mediated by these receptors. Conceiva- 
bly, therefore, other TRAF-domain proteins could interact 
with these homologous domains in Fas, TNF-RI, and p75- 
NGF-R. 
Previous analysis of the TRAF1 and TRAF2 proteins that 
bind to TNF-R2 failed to delineate the significance of the con- 
served C-terminal TRAF domain. Since the CAP-1 cDNA 
originally cloned during two-hybrid-based cDNA library 
screening encodes little more than the TRAF domain and given 
that this portion of CAP-1 (residues 384-540) is sufficient for 
interactions with the cytoplasmic domain of CD40 both in vitro 
and in two-hybrid assays, this finding suggests that one func- 
tion of the TRAF domain is to mediate interactions with TNF- 
R family receptors. In addition, we showed that this same 
region in CAP-1 is sufficient o mediate dimerization of CAP-1 
fusion proteins, suggesting yet another ole for the TRAF do- 
main. Previously it was shown that TRAF1 and TRAF2 can 
form homotypic and heterotypic dimers [23]. It is presently 
unknown whether CAP-I can dimerize with TRAFI or 
TRAF2. By analogy, however, it seems likely that CAP-I will 
be able to participate in heterodimer formation with at least 
some other known or unknown members of the TRAF family, 
since the TRAF-domain in CAP-1 appears to be sufficient for 
dimerization with itself. This possibility for various combina- 
tions of homo- and heterotypic dimers could then create oppor- 
tunities for specificity in signal transduction response which 
might be controlled both at the level of gene expression i  terms 
of which members of the TRAF-domain gene family that are 
expressed in any particular cell-type and at the level of protein- 
protein interactions between TRAF-domain-containing pro- 
teins and specific members of the TNF-R family. With regards 
to the former, preliminary results suggest that CAP-1 is widely 
expressed (our unpublished ata), like TRAF2, but unlike 
TRAF-1 which appears to be expressed in only spleen, lung, 
and testes [23]. However, specificity in the involvement of CAP- 
1 in signal transduction presumably can be achieved through 
its ability to interact with CD40 but not several other members 
of the TNF-R family, including TNF-R1, TNF-R2, and Fas. 
CAP-I and TRAF-2 both contain RING finger domains 
near their N-termini. This cysteine-rich structure represents a 
unique zinc-binding motif that has been found in over 40 pro- 
teins to date (reviewed in [24]). Thodgh RING-fingers may have 
other roles, in at least some circumstances they have been 
shown to bind to DNA [26 28]. Moreover, several viral tran- 
scriptional regulators including the Herpes Simplex virus im- 
mediate-early genes IEHBV, IEEHV, and IEl l0 contain 
RING fingers and deletion of this domain in IE110 has been 
reported to abolish its function as a trans-activator [29,30]. 
These findings raise the possibility that CAP-1 and TRAF2 
may participate directly in signal transduction from membrane 
to nucleus by analogy to the Stat proteins, which associate with 
the cytoplasmic domains of many cytokine receptors, dissociate 
from the receptor at the membrane upon ligand-induced phos- 
phorylation, and translocate into the nucleus where they bind 
to specific DNA sequences and participate in the regulation of 
gene expression (reviewed in [31]). Interestingly, CAP-1 also 
contains three and TRAF2 has two zinc-finger domains imilar 
to those first found in the Xenopus transcription factor TFII IA 
[25], thus further suggesting a potential role for these proteins 
in transcriptional regulation. However, at present i is unknown 
whether RING-finger domains constitute sequence-specific 
DNA-binding elements, and other potential functions for pro- 
teins that contain this structure are clearly possible, including 
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participation in protein-protein and protein-lipid interactions 
[24]. Though the precise role that CAP-1 plays in CD40-medi- 
ated signal transduction responses remains to be determined, 
the identification of CAP-1 and the demonstration of its homol- 
ogy with other TRAF-domain-containing proteins nevertheless 
represent significant advances in our understanding of the 
mechanisms by which CD40 and some other members of the 
TNF-R  family exert their potent biological effects in cells, 
Acknowledgements: We thank S. Elledge for the B-cell two-hybrid li- 
brary, E. Golemis and S. Hollenberg for other two-hybrid reagents, I. 
Stamenkovic and B. Seed from CD40 cDNAs, and C. Stephens for 
manuscript reparation. Dr. Sato is a recipient of a fellowship from the 
US Army Medical Research Development Command/Breast Cancer 
Research Inititative. Dr. Reed is a Scholar of the Leukemia Society of 
America. 
References 
[1] Clark, E.A. and Ledbetter, J.A. (1994) Nature 367, 425428. 
[2] Noelle, R.J., Ledbetter, J.A. and Aruffo, A. (1992) Immunol. 
Today 13, 431~433. 
[3] Lederman, S., Yellin, M.J., Covey, L.R., Cleary, A.M., Callard, 
R. and Chess, L. (1993) Curr. Opin. Immunol. 5, 439 444. 
[4] Armitage, R.J., Fanslow, W.C., Strockbine, L., Sato, T.A., 
Clifford, K.N., Macduff, B.M., Anderson, D.M., Gimpel, S.D., 
Davis-Smith, T., Maliszewski, C.R., Clark, E.A., Smith, C.A., 
Grabstein, K.H., Cosman, D. and Spriggs, M.K. (1992) Nature 
357, 80-82. 
[5] Hollenbaugh, D., Grosmaire, L.S., Kullas, C.D., Chalupny, N.J., 
Braesch-Anderson, S. Noelle, R.J., Stamenkovic, I., Ledbetter, 
J.A. and Aruffo, A. (1992) EMBO J. 11, 4313~,321. 
[6] Gauchat, J.-F., Henchoz, S., Mazzel, G., Aubry, J.-P., Brunner, 
T., Blasey, H., Life, P., Talabot, D., Flores-Romo, L., Thompson, 
J., Kishi, K., Butterfield, J., Dahinden, C. and Bonnefoy, J.-Y. 
(1993) Nature 365, 340-343. 
[7] Foy, T.M., Shepherd, D.M., Durie, F.H.,m Aruftb, A., Ledbetter, 
J.A. and NoeUe, R.J. (1993) J. Exp. Med. 178, 1567-1575. 
[8] Allen, R.C., Armitage, R.J., Conley, M.E., Rosenblatt, H., 
Jenkins, N.A., Copeland, N.G., Bedell, M.A., Edelhoff, S., 
Disteche, C.M., Simoneaux, D.K., Fanslow, W.C., Belmont, J. 
and Spriggs, M.K. (1993) Science 259, 990-993. 
[9] DiSanto, J.P., Bonnefoy, J.Y., Gauchat, J.F., Fischer, A. and de 
Saint Basile, G. (1993) Nature 361, 541-543. 
[10] Korthguer, U., Graf, D., Mages, H.W., Bri6re, F., Padayachee, 
M., Malcolm, S., Ugazio, A.G., Notarangelo, L.D., Levinsky, R.J. 
and Kroczek, R.A. (1993) Nature 361,539-543. 
[11] Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., 
Suematsu, S., Yoshida, N., Kishimoto, T. and Kikutani, H. (1994) 
Immunity 1, 167-178. 
[12] Durie, F.H., Fava, R.A., Foy, T.M., Aruffo, A., Ledbetter, J.A. 
and Noelle, R.J. (1993) Science 261, 1328-1330. 
[13] Smith, C.A., Farrah, T. and Goodwin, R.G. (1994) Cell 76, 959- 
962. 
[14] Stamenkovic, I., Clark, E.A. and Seed, S. (1989) EMBO J. 8, 
1403-1410. 
[15] Itoh, N. and Nagata, S. (1993) J. Biol. Chem. 268, 10932-10937. 
[16] Tartaglia, L.A., Ayres, T.M., Wong, G.H.W. and Goeddel, D.V. 
(1993) Cell 74, 845-853. 
[17] Rabizadeh, S., Oh, J., Zhong, L., Yang, J., Bilter, C., Butcher, U 
and Bredesen, D. (1993) Science 261,345-348. 
[18] Ruan, Y., Camerini, D. and Bredesen, D.E. (1994) Neurochemis- 
try, in press. 
[19] Vojtek, A.B., Hollenberg, S.M. and Cooper, J.A. (1993) Cell 74, 
205-214. 
[20] Sato, T., Hanada, M., Bodrug, S., Irie, S., Iwama, N., Boise, H.L., 
Thompson, B.C., Golemis, E., Fong, L., Wang, H.-G. and Reed, 
J.C. (1994) Proc. Natl. Acad. Sci. USA 91, 9238-9242. 
[21] Durfee, T., Becherer, K., Chert, E-L., Yeh, S.-H., Yang, Y., 
Kilburn, A.E., Lee, W.H. and Elledge, S.J. (1993) Genes Dev. 7, 
555 569. 
[22] Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., 
Sameshima, M., Hase, A., Seto, Y. and Nagata, S. (1991) Cell 66, 
233-243. 
[23] Rothe, M., Wong, S.C., Henzel, W.J. and Goeddel, D.V. (1994) 
Cell 78, 681-692. 
[24] Freemont, ES. (1993) in: Ann. NY Acad. Sci. p. 174-192. 
[25] Berg, J.M. (1990) J. Biol. Chem. 265, 6513-6516. 
[26] Lovering, R., Hanson, I.M., Borden, K.L.B., Martin, S., O'Reilly, 
N., Evan, G.I., Rahman, D., Pappin, D.J.C., Trowsdale, J. and 
Freemont, ES. (1993) Proc. Natl. Acad. Sci. USA 90, 2112- 
2116. 
[27] Tagawa, M., Sakamoto, T., Shigemoto, K., Matsubara, H., 
Tamura, Y., Ito, T., Nakamura, I., Okitsu, A., Imai, K. and 
Taniguchi, M. (1990) J. Biol. Chem. 265, 20021 20026. 
[28] Reddy, B., Kloc, M. and Etkin, L.D. (1991) Dev. Biol. 148, 107- 
116. 
[29] Everett, R.D. (1988) J. Mol. Biol. 202, 87-96. 
[30] Zhu, X., Chen, J., Young, C.H.S. and Silverstein, S. (1990) 
J. Virol. 64, 4489-4498. 
[31] Darnell, J.E., Kerr, I.M. and Stark, G.R. (1994) Science 264, 
1415-1412. 
